D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
D3/Penta 21 临床试验设计:一项随机非劣效性试验,包含嵌套的药物许可子研究,旨在评估多替拉韦和拉米夫定固定剂量制剂在维持 2 至 15 岁 HIV-1 感染儿童病毒学抑制方面的疗效。
期刊:Contemporary Clinical Trials
影响因子:
doi:10.1016/j.cct.2024.107540
Turkova, Anna; Chan, Man K; Kityo, Cissy; Kekitiinwa, Adeodata R; Musoke, Philippa; Violari, Avy; Variava, Ebrahim; Archary, Moherndran; Cressey, Tim R; Chalermpantmetagul, Suwalai; Sawasdichai, Kanokkorn; Ounchanum, Pradthana; Kanjanavanit, Suparat; Srirojana, Sakulrat; Srirompotong, Ussanee; Welch, Steven; Bamford, Alasdair; Epalza, Cristina; Fortuny, Clàudia; Colbers, Angela; Nastouli, Eleni; Walker, Simon; Carr, Dan; Conway, Magda; Spyer, Moira J; Parkar, Nazia; White, Iona; Nardone, Alessandra; Thomason, Margaret J; Ferrand, Rashida A; Giaquinto, Carlo; Ford, Deborah